Recent News

• 11.04.2026 - Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
• 11.02.2026 - Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
• 10.01.2026 - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 09.01.2026 - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.31.2026 - Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
• 08.13.2026 - Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
• 08.10.2026 - Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
• 08.03.2026 - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 07.30.2026 - Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
• 07.30.2026 - Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Recent Filings

• 11.02.2026 - 8-K Current report
• 11.02.2026 - EX-99.1 EX-99.1
• 10.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.22.2026 - 8-K Current report
• 10.19.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.14.2026 - 8-K Current report
• 10.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.25.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.25.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors